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An association of microbial agents and autoimmunity has 
been suggested for the pathogenesis of psoriasis. Mycobac-
teria are common environmental microbes and their anti-
gens, especially the highly conserved mycobacterial 65-kDa 
heat shock protein (hsp65), have been implicated in the 
pathogenesis of autoimmune arthritis and other idiopathic 
diseases. In this context, we investigated a possible mycobac-
terium-induced humoral immune response in psoriasis. Sera 
from 17 patients with chronic plaque-type psoriasis were 
studied by immunoblotting using the whole sonicate of My-
cobacterium tuberculosis and purified recombinant mycobacter-
ial hsp65 . Immunoblot analysis demonstrated that 58% of 
the psoriasis patients compared to patients with acne and 
OLE, and normal controls showed strong antibody activity to 
65-kDa and 48/45 doublet antigens from M. tuberculosis son-
icate, whereas 47% of the patients showed antibody activity 
to mycobacterial hsp65. Only 10- 20% of the patients had an 
antibody response to 16-kDa and 80-kDa antigens. Similar 
A utoimmunity and microbial agents have often been suggested to playa role in the pathogenesis of psoriasis [1- 7]. Previous studies have clearly shown that some psoriatic flares are associated with microbial infection and colonization, and the removal of these microbial 
foci has resulted in clearing of the disease in some cases [4,6] . 
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antibody activity to 65 kDa and 48/45 kDa was also found 
consistently with eight different sonicated mycobacterial 
species by immunoblotting, indicating that these seroreactive 
antigens are crossreactive and are present in common envi-
ronm~ntal mycobacteria. Antibody activities to both myco-
bactenal 65-kDa and hsp65 showed a positive correlation 
(r= 0.76) with the psoriasis disease activity, whereas antibod-
ies to 48/45-kDa doublet antigens showed a weak correla-
tion (r = 0.54). By enz~m~-lin~ed immunosorbent assay 
(ELISA), 47% of the psonasls patients showed significantly 
elevated antibody titers to hsp65 (p < 0.003) as compared to 
control groups, and the antibody response by ELISA also 
sl:owed a. si.gnifica~t positive c~rrelat~on (r = 0.76) with 
disease activity .. Antl-~ycobactenal antibody activity may be 
related to seventy of disease and may be useful in monitoring 
disease activity in psoriasis. ] Invest Dermatol 100:87-92, 
1993 
Mycobacteria have long been suspected of having an etiologic 
rol~ in .autoimmune and other !diopathi~ diseases [8,9]. Detailed 
antlgeruc analYSIS of several dom111ant antigens of mycobacteria has 
resulted in their identification as members of highly conserved heat 
shock or stres~ protein families. [10,11]. H~at shock proteins (hsp) 
are a focus of 111terest as potential antigens 111 the autoimmune dis-
eases. They are highly immunogenic proteins that show a high 
degree of sequence homology between many bacterial and human 
proteins [11-13]. 
Autoimmunity to hsp may be explained on the basis of so-called 
antigenic mimicry [9 ~1.1,1~]. Such ~ path?logic mechanism may 
underly human arthntlc disorders 111 wluch an association with 
previous bacteri~l infectior~ has been.suggested [14,15]. The notion 
that mycobactena may be 111volved 111 autoimmune diseases is fur-
the~ sUl?ported by th~ exper!m~ntal autoimmune ajuvant arthritis, 
which IS morphologically slmtiar to human rheumatoid arthritis 
[14,15]. In adjuvant arthritis, mycobacterial hsp65, the well-charac-
terized bacterial hs~, was the a.ntigen considered to be responsible 
for the pat.hogenesls of the disease [13-15]. In addition, an in-
creased antibody and! -cell responses to mycobacterial hsp65 has 
been sho~nto occur 111human rh~umatoid arthritis [15]. 
. In pson~sls, some pat~ents exlublt ~ymptoms of arthritis [16]. In 
v~ew of tillS all? of the 111~reaslng eVidence that mycobacteria may 
directly or llldlfe~tly be I?volved 111 the pathogenesis of autoim-
mune and other diseases With u~known etiology [5,8,9], we investi-
gated the presence of serum antibody responses of psoriasis patients 
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Table I. Correlation of the Serum Anti-Mycobacterial Antibody Response with the Disease Activity 
and Other Clinical Parameters of Psoriasis Patients 
C linical Status' 
Anti-Mycobacterial Antibody Activity 
Arthropathic Complaints 
Patient 48/45-kDaa 65-kDaa hsp65b Disease Activity PAS I Score at the Time of Sample Collection 
1 +++ +++ 
2 +++ +++ 
3 +++ +++ 
4 ++ ++ 
5 ± ++ 
6 + ++ 
7 ++ + 
8 + + 
9 + + 
10 ++ ± 









































, Increasing intensity of the antibody activity (- to ++t indicated no bands to strong bands, respectively) as measured visually by inul1unoblotting using M. lllberwlosis sonicate. 
• Increasing 00 values (- to +++ indicated the 00 below 0.2 and above 0.7, respectively) in ELISA using purified recombinant mycobacterial hsp65. 
, Clinical parameters. Disease activity is evaluated by the status (dynamics) of the disease condition as compared to one of more previous visits: +, -, and 0 are indicated as 
progression, regression, and stability of the disease cond ition. PASI scores arc evaluated as reported earlier [17J. Arthropathic complaints of these patients were defined as described in 
Malerials alld Methods. 
to mycobacterial hsp65 and other mycobacterial antigens. Our 
study demonstrated that psoriatic patients had significant IgG anti-
body against mycobacterial hsp65 and other dominant mycobacter-
ial antigens of various molecular sizes as compared to normal con-
trols. This antibody response was found to be positively correlated 
with the disease activity. 
MATERIALS AND METHODS 
Patients Sera from 17 chronic plaque type psoriasis patients were 
studied. There were 13 men and four women, age range 29-71 
years. All were suffering from severe plaque-form psoriasis unre-
sponsive to topical therapy. Duration of the disease of these patients 
was from 4 to 41 years . The status of disease was scored by means of 
the psoriasis area severity index (P ASI), using the sum of mean 
erythema, thickness, area of the involved skin, and scaling [17]. The 
disease activity as compared to previous visits has been scored as 
regressive (-), stable (0), progressive (+) , or strongly progressive 
(++). Clinical parameters of individual patient are illustrated in 
T able I. All patients were treated with oral cyclosporin A with or 
without conventional topical corticosteroid treatment at the time of 
sample collection. None of the patients had any clinical history of 
tuberculosis or leprosy. Although 10 patients had a history of 
arthropathic complaints, only five had mild to moderate complaints 
at the time of sample collection (Table I). Arthropathic complaints 
of these patients were defined by one or more of the following 
clinical symptoms; pain in the joints, redness, swelling of the joints, 
or impairment of daily living activities. None of the patients had 
severe arthritis. Control sera used in this study were obtained from 
five acne patients, six DLE patients, and 15 normal healthy individu-
als. 
Antigen Preparations The mycobacterial antigens were pre-
pared from sonicates of fresh bacilli as described previously [18,19). 
The species used were Mycobacterium tuberculosis, Mycobacterium bOIJis 
BCG, Mycobacterium avium, Mycobacterium intracellu lari, Mycobacter-
ium go rdol1ae, Mycobacterium Illarillium, Mycobacterium u/ceral1s, Myco-
bacterium kansassi, and Mycobacterium duva li. Strains of these myco-
bacterial species are similar to those described in our previous report 
(19) . 
The native 65-kDa mycobacterial hsp was derived from Esche-
richia coli K12 carrying M. bOIJis BCG recombinant DNA with the 
65-kDa protein gene [20), and was obtained in purified form from 
Dr. J. van Embden, National Institute of Public Health, Bilthoven, 
The Netherlands. 
Sodium Dodecylsulfate-Polyacrylamide Gel Electrophore-
sis (SDS-PAGE) and Immunoblotting SDS-PAGE was per-
formed in slab gels (12%) in discontinuous Tris-buffer system as 
described previously [18,19). All antigen preparations were incu-
bated with sample buffer at 65 0 C for 20 min. Pre-evaluated concen-
tration of 15 ILg of proteins were applied from different species of 
mycobacterial sonicates, whereas 2 ILg were loaded from purified 
mycobacterial hsp65. Proteins were transferred to nitrocellulose 
papers according to Towbin et al [21 J, and immunoblotting was 
performed with sera of optimal dilution (1: 100) as previously de-
scribed [18]. The bound antibodies were visualized by using HRP-
conjugated goat anti-human IgG diluted at 1 : 4000 (Tago, Burlin-
game, CA) as described previously (18). 
Enzyme-Linked Immunosorbent Assay (ELISA) ELISA was 
performed essentially according to our earlier report [18), except 
that in the present study afli.niCJ: -purifi~d mycobacteri~l hsp65 (0.5 
IL~ p~r well) was used as the coatlllg antigen and the optimum serum 
dt!~tlon used was 1 : 100. Serum IgG, IgM, and IgA antibody classes 
agalllst mycobactenal hsp65 were determined in all patient groups 
and normal individuals. 
RESULTS AND DISCUSSION 
Antibody Response to M. Tuberculosis Antigens Immunoblot 
~n.a~ysis usin~ total sonicate of ~. t~lberC!/losis was employed for the 
lIlItial screenlllg of sera of psonasls patients. Our results demon-
strated that more than 58% of the psoriasis patients showed a consist-
ent strong antibody reactivity to antigens of apparent molecular 
masses of.65-kDa and 48/45-kpa doublet as compared to control 
gro~ps. Flgu.re.1 sh?ws the vanable serum IgG antibody reactivity 
of eight pSOrIaSIS patients toM. tuberculosis antigens of various molec-
ular weights. Antibody activity to 16-kDa and 80-kDa antigens was 
fou.nd only in 10-20% of the patients, whereas most of the psoriasis 
patle.nts showed a mode~ate activity to 40 kDa and to multiple bands 
of high - molecular-~elght antigens. The intensity of the bands 
reflects the antibody titers 111 the following order: + to 3+ indicate 
the moderate to the highest intensity of the bands at a dilution of 
1 : 100. Because some of the control sera also showed weak antibody 
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Figure 1. Representative example showing serum IgG antibody responses 
of eight patients with plaque type psoriasis (lalles 1-8) and a pool sera from 
normal controls (lalle 9) toM. tuberCII losisSOlUcate, detected by InllTIunoblot-
ting. Sera were diluted 1: 100. Molecular weights in kilodalton (kDa) are 
shown at left. 
activity (±), especially to the 65 kDa and occasionally ~o 48/45 
kDa, we used ± intensity as the cutoff value for the evaluatIOn of the 
positive antibody titer in psoriasis patients. Mor~over, ~n~ibody ac-
tivity could be detected up to 1 : 500 to 1 : 1000 111 psonasls patl~nts 
who showed high titer to 65 kDa and 48/45 kDa. At these dtlu-
tions, all control sera gave no staining. The latter was also taken as a 
criteria of evaluation of + + and + + + antibody activity of psoriasis 
patients. . . . 
It is important to note that serum antibodies to high - molecular-
weight mycobacterial antigens has al~obeen !dentifi.ed as a p.referen-
tial antibody response to mycobactena 111 patients with autouumune 
diseases and autoimmune type dermatoses [22]. Some of these my-
cobacterial antigens recognized by psoriasis sera are known to be the 
major crossreactive antigens involved ~n . the im~nune response of 
active mycobacterial diseases [18,23]. It IS 111terest111g that lughantl-
body activity of psoriasis patients to 48/45-kDa doublet antigens 
has not been shown to occur consistently even in active mycobac-
terial diseases. However, in our preliminary report we demonstrated 
that patients with Crohn's disease showed a significant. antibody 
response to 48/45-kDa antigens. * ~n tl.le other h~nd, patients with 
Crohn's disease did not show any slgmficant antibody response to 
65-kDa antigen. Serum samples obtained from patients with acne 
and DLE as well as normal controls showed no significant antibody 
activity to these antigens, although DLE patients showed a certain 
antibody response to antigens other than 65 kDa and 48/45 kDa 
(data not shown). 
Occurrence of Antibody Response to Similar Antigens from 
Other Mycobacterial Species Immunoblots containing soni-
fied extract of eight different mycobacterial species were developed 
with a pool of positive sera from psoriasis patients to determine 
whether immunodominant protein bands identified from M. tlJber-
Cil losis are also present in other mycobacterial species, especially 
those that are known to be associated with dermatologic lesions 
[24,25]. Indeed, similar 65-kDa and 48/45-kDa bands were ob-
• Das PK, Blaauwgeers JLG, Slob AW, Yong S, Rambukkana A: Myco-
bacterial antibody response in relation to Crohn's disease (abstr). Gastroen-
terology 96(part 2):A111, 1989. 
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served in all the mycobacterial species tested (Fig 2), indicating that 
these seroreactive mycobacterial antigens are cross-reactive antigen 
components [18]. This was further confirmed by absorption of 
pooled positive sera with different mycobacterial sonicates (data not 
shown). Non-tuberculous mycobacteria have been found in associa-
tion with infection of the skin and subcutaneous tissues [24]. In 
addition, M. milritllllll and M. II/cemus are known to be predomi-
nantly skin pathogens with affinity to the low-temperature areas of 
the body, and some dermatologic lesions and ulcers are known to be 
caused by M. Ilvillmilltracel/uillre, M. kallsllssi, and M. gordollae [25,26]. 
It may be that persistence of serum antibodies in psoriasis patients is 
due to previous skin infections with these mycobacterial species 
because mycobacteria are quite widespread in the environment. 
Antibody Response to Mycobacterial hsp65 The finding of 
serum antibody response to 65-kDa antigen from various species of 
mycobacteria is of particular interest. Mycobacterial 65-kDa is 
known to be a common bacterial antigen [10,20] and belongs to the 
highly conserved heat shock protein family of hsp60 that has been 
implicate? in c~oss-reactive autoimn:unity in arthritis [14]. There-
fore, we lI1vestigated the serum antibody activity of psoriasis pa-
tients to purified mycobacterial hsp65 derived from recombinant 
DNA strain of E. co~i K12 [20] . It is inter~sting that those patients 
who had strong antibody response to antigen from mycobacterial 
sonicates in immunoblotting showed significantly elevated anti-
body reactivity to mycobacterial hsp65 in immunoblotting (Fig 
3A). Individual anti-mycobacterial hsp65 IgG antibody levels in 
ELISA are shown in Fig 3B. Because no differences were found 
between normal and control non-psoriatic patient groups, the opti-
cal density (OD) corresponding to 0.2 was taken as the cutoff point 
or normal upper limit. Accordingly, we found that 47% of psoriasis 
patients showed significantly elevated serum IgG antibody titer to 
mycobacterial hsp65 (p > 0.003). None of the psoriasis patients 
showed elevated IgM or IgA antibody response to mycobacterial 
hsp65 in ELISA (data not shown). 
2 3 4 5 6 7 8 
Figure 2: Immu~oblot analysis of total sonicates of various mycobacterial 
specIes With pOSItive pool sera from five psoriasis patients (diluted 1: 100). 
Latlcs: 1, M. avilllll; 2, M. lIIarillilllll; 3, M. IIlceratls; 4, M. kamasi; 5, M. 
gordollae; 6, M. dllvali; 7, M. itltracellulari; 8, M. bovis BeG. Note the consist-
ent strong antibody activity to 65-kDa and 48/45-kDa antigens in all myco-
bacterial species. 
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Figure 3. A) Immunoblot analysis showing the serum antibody activity to mycobacterial hsp65 in psoriasis patients with varying intensities. Sera were 
grouped as strong positive (Iatles 1 and 2), moderate positive (laue 3), and weak positive (Iatle 4). Most of the normal serum reactivity corresponds to the 
intensity of laue 4. B) Individual serum IgG antibody titers to mycobacterial hsp65 in patients with psoriasis, acne, DLE, and normal controls in ELISA. Sera 
were di luted 1 : 100. 
The variability in the antibody response to mycobacterial hsp65 
and other immunodominant antigens, both in intensity and specific-
ity, in psoriasis patients, is intriguing. When the data were exam-
ined for the association with disease activity of psoriasis, we found a 
significant positive correlation between the anti-mycobacterial 
serum IgG response and the clinical parameters of the patients. 
Antibodies to mycobacterial 65-kDa and hsp65 in immunoblotting 
showed an excellent relationship with the disease activity (r= 0.76), 
whereas antibodies to 48/45 kDa showed a weak correlation (r = 
0.54). r value was calculated as the relative antibody activity in 
relation to the serum dilution (relative intensity of bands as a param-
eter of + to +++ positivity) . Moreover, anti-hsp65 ELISA titers 
showed a similar correlation coefficient (r = 0.76) with disease 
activity. Table I summarizes the overall comparison of antibody 
response (both immunoblotting and anti-hsp65 ELISA titers) and 
the clinical parameters of the psoriasis patients. It is worth noting 
that the patients who developed a very severe disease had the most 
prominent antibody response to various mycobacterial antigens as 
well as the highest ELISA titers to mycobacterial hsp65. Among the 
patients who showed strong anti-mycobacterial antibody response 
(+ to +++ in immunoblotting and ELISA), 77% had the active 
form of psoriasis. On the other hand, none of the patients who 
showed weak (±) or no (-) antibody response (corresponding to 
antibody activity of control groups) had disease activity and thus 
showed a negative correlation. We found no correlation of anti-
mycobacterial antibody activity with arthropathic complaints of the 
patients. 
Although the present data do not necessarily suggest a pathogenic 
rol e of anti-mycobacterial antibodies in psoriasis patients, serum 
antibody responses to specific group of mycobacterial antigens 
could be regarded as an indicator for an increased risk of developing 
psoriasis in genetically predisposed individuals. This possibility 
needs to be investigated further. However, no association was found 
between the antibody activity and the duration of the treatment of 
the disease. We have followed up some of the patients who are 
undergoing cyclosporin A treatment for up to 3 - 6 months and 
found no difference in antibody activity to mycobacterial antigens 
during and after the treatment. However, this does not exclude the 
possibility that rnajo.r deviations in antibody titer may be present 
before the cyclosponn A treatment. In order to evaluate the direct 
effect of cyclosporin A treatment on anti-mycobacterial antibody 
titer of psoriasis patients, further studies are needed. 
The stress p~ot~ins a~e important targets of the immune response 
to my~obacten~11l1fectlo~1 and have been implicated for the patho-
geneSIS. of aut01m~1Un~ d~seases [9.' 11,12]. The major stress protein 
recogmzed by antibodies 111 bactenal infection is hsp60. In addition, 
there are m~ny microbial .candidates that account for the develop-
ment of antl-hsp 60/65 1~I~une response in humans [9]. Signifl-
candy e1e.vated .antlbody b1l1d1l1g to mycobacterial hsp65 has been 
reported 111 patients With rheumatoid arthritis [27], Beh\=et's syn-
drome . [2~], and super~cial candidiasis [29] . This suggested that 
hsp60 IS ltkely to be an Immune target in many bacterial infections 
[9,1 ~]. M.oreover, p:eviolls studies have shown that a polyclollal 
rabbit antiserum agalllst mycobacterial hsp65 recognized a similar-
molecular-size protein from streptococcus strains, suggesting that 
some of the streptococcal antigens are cross-reactive with mycobac-
terial ~lsp65 [28]. A !ecent report on group A streptococcal cell 
wall -1I1duced arthrttlS III rats also presented evidence of T -cell -
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based cross-reactivity with M. t,jberwlosis antigens [30] and has 
shown thatrretreatment with mycobacterial hsp65 prevented the 
arthritis [31 . In this regard, it is interesting to note that streptococ-
cal infection is considered to be a trigger of guttate psoriasis, which 
may precede chronic plaque type. psorias~s [7 ,32] . Su~h clinical ob-
servations have been partly expla1l1ed by Immunologic cross-reaCti-
vity between streptococcal proteins and components of the human 
skin [33] . Published data further suggest that a conserved part of the 
streptococci M protein may trigger the psoriatic process [33]. In this 
context, it is pertinent to note that we have recently shown that two 
novel MoAbs (Ne5/Nd4) raised against mycobacterial hsp65 cross-
reacted with human epiderma l cytokeratin 1/2 [34,35]. In psoria-
sis, this particular epitope was found to be absent in lesional 
sites. 
These relevant findings, together with our present observation of 
elevated antibody response of psoriasis patients to mycobacterial 
h sp65, suggested that shared or common anti~ens such as myco?ac-
terial or streptococcal hsp might play a role 111 the pathogenesIs of 
psoriasis. Moreover, psoriasis has been associated with an increased 
frequency of certain human leukocyte antigen (HL~) ha~lotypes 
including HLA-Cw6, B 13, B 17, and B27 [36,37]. It IS pOSSible. that 
an association between HLA haplotype and the observed vanable 
serum antibody response to mycobacterial hsp65 and other myco-
bacterial antigens exists in psoriasis patients. Finally, our study fur-
ther suggests that because mycobacteria are ubiquitous environmen-
ta l pathogens, and because the mycobacterial antigens are potent 
immunomodulators, certain mycobacterial antigens may trigger 
psoriasis in genetically predisposed individuals. On th~ other hand, 
most of the patients in the present study are BCG vacc1l1ated. Con-
sequently, an alternative explanation can be that the mycobacterial 
antibodies are somehow stimulated in active psoriasis, but nonspeci-
fica lly. Therefore, further studies in a non- BCG-immunized popu-
lation would be of interest in this respect. 
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